Article Detail - JF Part B
Billing and Coding: MolDX: Minimal Residual Disease Testing for Solid Tumor Cancers (A58454) - R18 - Effective June 25, 2026
Date Posted: June 25, 2026
This Billing and Coding Article has been revised under contract numbers: 02102 (AK), 02202 (ID), 02302 (OR), 02402 (WA), 03102 (AZ), 03202 (MT), 03302 (ND), 03402 (SD), 03502 (UT), and 03602 (WY).
Effective Date: Multiple dates
Summary of Changes:
Under Article Text revised Table 1 row 3 to add "NeXT Personal - Personalized WGS Assay Design + Plasma Series Bundle (Personalis, Inc)". Under subheading Additional Test-specific Indications, Limitations and Instructions revised 3rd sentence to add "or stage IV (NeXT Personal)". This revision is due to a new covered test that has successfully completed a TA and is effective for 3/16/2026.
Under Article Text revised Table 1 row 9 to add "TrueMRD Assay Design + single Plasma Test (Veracyte, Inc)". Revised Table 1 row 10 to add "TrueMRD single Plasma Test (Veracyte, Inc)". Under subheading Additional Test-specific Indications, Limitations and Instructions revised 2nd sentence to add "and muscle invasive bladder cancer (TrueMRD)". This revision is due to a new covered test that has successfully completed a TA and is effective for 11/24/2025.
Visit the Noridian Molecular Diagnostic Services webpage to view the Active MolDX LCDs or access it via the CMS MCD.